Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report

NeuroImage: Clinical

卷:32

Luciano Minuzzi¹  Stephen R. Arnott²  Roumen Milev³  Stefanie Hassel⁴  Valerie H. Taylor⁵  Benicio N. Frey⁶  Sidney H. Kennedy⁷  Nikita Nogovitsyn⁸  Raymond W. Lam⁸  Daniel J. Müller⁸  Jee Su Suh⁹  Pedro L. Ballester⁹  Stephen C. Strother¹⁰  Roberto B. Sassi¹⁰ 

[1] Department of Medical Biophysics, University of Toronto, ON, Canada;

[2] Institute of Medical Science, University of Toronto, Toronto, ON, Canada;

[3] Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada;

[4] Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;

[5] Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada;

[6] Department of Psychiatry, University of Toronto, Toronto, ON, Canada;

[7] Departments of Psychiatry and Psychology, Queen’s University, and Providence Care, Kingston, ON, Canada;

[8] Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada;

[9] Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada;

[10] Rotman Research Institute, Baycrest, Toronto, ON, Canada;

关键词: Treatment response;    Major depressive disorder;    Brain age;    Machine learning;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objectives: Previous studies suggest that major depressive disorder (MDD) may be associated with volumetric indications of accelerated brain aging. This study investigated neuroanatomical signs of accelerated aging in MDD and evaluated whether a brain age gap is associated with antidepressant response. Methods: Individuals in a major depressive episode received escitalopram treatment (10–20 mg/d) for 8 weeks. Depression severity was assessed at baseline and at weeks 8 and 16 using the Montgomery-Asberg Depression Rating Scale (MADRS). Response to treatment was characterized by a significant reduction in the MADRS (≥50%). Nonresponders received adjunctive aripiprazole treatment (2–10 mg/d) for a further 8 weeks. The brain-predicted age difference (brain-PAD) at baseline was determined using machine learning methods trained on 3377 healthy individuals from seven publicly available datasets. The model used features from all brain regions extracted from structural magnetic resonance imaging data. Results: Brain-PAD was significantly higher in older MDD participants compared to younger MDD participants [t(147.35) = -2.35, p < 0.03]. BMI was significantly associated with brain-PAD in the MDD group [r(155) = 0.19, p < 0.03]. Response to treatment was not significantly associated with brain-PAD. Conclusion: We found an elevated brain age gap in older individuals with MDD. Brain-PAD was not associated with overall treatment response to escitalopram monotherapy or escitalopram plus adjunctive aripiprazole.

【 授权许可】

Unknown